Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
Related news for (JSPR)
- MoBot’s Stock Market Highlights – 07/09/25 01:00 PM
- Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
- 24/7 Market News Snapshot 09 July, 2025 – Jasper Therapeutics, Inc. Common Stock (NASDAQ:JSPR)
- Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
- Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress